Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
Reuters NewMedia - Thursday, July 9, 2009
Ransdell Pierson
* Merck says safety profile could be drawing card
* Merck shares little changed in after-hours trade (Adds shares)
NEW YORK, July 9 - Merck & Co on Thursday said U.S. regulators had widened the approved use of its Isentress HIV treatment to include patients who have not yet been treated for infections with the virus that causes AIDS.
Isentress, the only approved member of a new family of anti-HIV medicines known as integrase inhibitors, has been available since late 2007 for patients who have failed to benefit from prior treatment with HIV medicines.
The new indication could help boost sales of the drug, which posted revenue last year of $361 million and is often used with the widely prescribed combination treatment Truvada sold by Gilead Sciences Inc (GILD.O: Quote, Profile, Research, Stock Buzz).
Isentress blocks a protein called integrase, thereby preventing genetic material from the virus from integrating with human cells. Gilead is in the process of developing a similar medicine.
Merck said Isentress was well tolerated in clinical trials -- with relatively few side effects.
Isentress and standard treatment together proved about twice as effective at suppressing HIV in clinical trials as standard treatment alone among patients who had previously failed to benefit from HIV drugs.
In separate trials among patients not previously treated for HIV, Isentress and Truvada together were slightly more effective at driving down HIV levels than Truvada combined with efavirenz -- an older Merck HIV treatment.
Merck shares were trading at $26.90 after-hours, little-changed from their closing price of $27.01 Thursday on the New York Stock Exchange. (Reporting by Ransdell Pierson; Editing by Gary Hill) (Reuters Messaging: ransdell.pierson.reuters.com@reuters.net; 646-223-6034; ransdell.pierson@reuters.com)
090709
RE090707
Copyright © 2009 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .